Jiang Wenxiao, Chetry Mandika, Pan Shuya, Wang Longyi, Zhu Xueqiong
Department of obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China.
J Cancer. 2021 Mar 5;12(9):2654-2664. doi: 10.7150/jca.54595. eCollection 2021.
To explore the prognosis of Galectins (LGALS) expression on patients with ovarian cancer, the prognosis of LGALS members in ovarian cancer was retrieved and analyzed by using 'Kaplan-Meier plotter' database. The relation of LGALS to overall survival (OS) was evaluated according to histological subtypes, clinical stages and pathological grade. Quantitative real-time polymerase chain reaction and western blot were used to detect the mRNA and protein expression of LGALS in ovarian cancer and normal ovarian cells. Immunohistochemistry was applied to evaluate the different expression of LGALS between cancer and normal tissues. In total patients with ovarian cancer, LGALS4, LGALS8, LGALS10 and LGALS13 mRNA levels were related to a better OS, and LGALS1 to a worse OS. LGALS1 predicted a worse OS in women with serous, stages III+IV or grade II ovarian cancer. LGALS4 predicted a better OS in patients with endometrioid, stages I+II or grade III ovarian cancer. LGALS10 predicted a longer OS in females with serous, all stages, or grade III cancer. LGALS8 overexpression was related to a better OS in all stages. Notably, mRNA and protein expressions of LGALS4, LGALS10 and LGALS13 were decreased in cancer cells than those in normal cells (<0.05). Additionally, the immunostaining score of LGALS8, LGALS10 and LGALS13 expression were lower but LGALS1 was higher in caner tissues than those in normal tissues (<0.001). In conclusion, LGALS10 possibly is a valuable biomarker for predicting a favorable prognosis in patients with ovarian cancer, especially with serous, all stages and grade III cancer.
为探讨半乳糖凝集素（LGALS）表达对卵巢癌患者预后的影响，利用“Kaplan-Meier plotter”数据库检索并分析了卵巢癌中LGALS成员的预后情况。根据组织学亚型、临床分期和病理分级评估LGALS与总生存期（OS）的关系。采用定量实时聚合酶链反应和蛋白质免疫印迹法检测卵巢癌细胞和正常卵巢细胞中LGALS的mRNA和蛋白表达。应用免疫组织化学评估癌组织和正常组织中LGALS的不同表达。在所有卵巢癌患者中，LGALS4、LGALS8、LGALS10和LGALS13的mRNA水平与较好的总生存期相关，而LGALS1与较差的总生存期相关。LGALS1预测浆液性、III + IV期或II级卵巢癌女性的总生存期较差。LGALS4预测子宫内膜样、I + II期或III级卵巢癌患者的总生存期较好。LGALS10预测浆液性、各期或III级癌症女性的总生存期较长。LGALS8过表达与各期较好总生存期相关。值得注意的是，癌细胞中LGALS4、LGALS10和LGALS13的mRNA和蛋白表达低于正常细胞（<0.05）。此外，癌组织中LGALS8、LGALS10和LGALS13表达的免疫染色评分低于正常组织，而LGALS1的免疫染色评分高于正常组织（<0.001）。总之，LGALS10可能是预测卵巢癌患者，尤其是浆液性、各期和III级癌症患者良好预后的有价值生物标志物。
